Guillain Barre Sendromu
Özet
Guillain-Barré Sendromu (GBS), enfeksiyon sonrası gelişen, periferik sinirlerin ve spinal köklerin otoimmün tutulumuyla karakterize, akut flask paralizinin en sık görülen nedenidir. Klinik tablo genellikle alt ekstremitelerde başlayan, arefleksi ile seyreden progresif kas güçsüzlüğü ile kendini gösterir ve tanı aşamasında BOS bulguları ile elektrofizyolojik çalışmalar temel alınır. Tedavide destekleyici bakımın yanı sıra intravenöz immünglobulin (IVIG) veya plazma değişimi (PLEX) gibi immünoterapi yöntemleri etkin şekilde kullanılır. Hastalık çocuklarda ve erişkinlerde değişken bir klinik seyir gösterse de, uygun müdahale ile iyileşme süreci optimize edilebilmektedir.
Guillain-Barré Syndrome (GBS) is an immune-mediated polyneuropathy typically characterized by acute, progressive muscle weakness and areflexia, often occurring after an infectious event. Diagnosis relies on clinical presentation, electromyography, and cerebrospinal fluid findings, which often show albumino-cytological dissociation. Primary management involves supportive care combined with immunomodulatory treatments such as intravenous immunoglobulin (IVIG) or plasma exchange (PLEX). While clinical severity and recovery rates vary, timely intervention significantly improves outcomes and reduces long-term neurological sequelae.
Referanslar
Kliegman RM, Blum NJ, St Geme III JW, Shah SS, Tasker RC, Wilson KM. Nelson textbook of pediatrics- Guillian-Barré Syndrome. 21, İnternational ed. Canada: Elsevier; 2020; 3335-9p
van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10(8): 469-82.
Johnston M, Ouvrier R. Aicardi’s Diseases of the Nervous System in Childhood 4th Edition. 4th ed. ; 2018; 1226-32p.
Leonhard SE, Mandarakas MR, Gondim FA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology 2019; 15(11): 671-83.
Owecki MK, Skalski P, Magowska A. Jean-Alexandre Barré (1880-1967). J Neurol 2018; 265(4): 987-9.
Guillain G. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquode cephalo-rachidien sans reaction cellulaire: remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bell Mem Soc Med Paris 1916; 40: 1462-70.
Draganesco H, Claudian J. Sur un cas de radiculu-névrite curable (syndrome de Guillain-Barré) apparue au cours d’une ostéomyélite du bras. Rev Neurol (Paris) 1927; 2: 517-21.
Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366(24): 2294-304.
Jones HR, Jr. Guillain-Barré syndrome: perspectives with infants and children. Semin Pediatr Neurol 2000; 7(2): 91-102.
Morris AM, Elliott EJ, D'Souza RM, Antony J, Kennett M, Longbottom H. Acute flaccid paralysis in Australian children. J Paediatr Child Health 2003; 39(1): 22-6.
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36(2): 123-33.
Carroll JE, Jedziniak M, Guggenheim MA. Guillain-Barré syndrome. Another cause of the "floppy infant". Am J Dis Child 1977; 131(6): 699-700.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016; 388(10045): 717-27.
Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366(9497): 1653-66.
Webb AJ, Brain SA, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry 2015; 86(11): 1196-201.
Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA. The occurrence of Guillain-Barre syndrome within families. Neurology 2004; 63(9): 1747-50.
Naik KR, Saroja AO, Patil BP. Familial Guillain-Barré syndrome: First Indian report. Ann Indian Acad Neurol 2012; 15(1): 44-7.
Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010; 74(7): 581-7.
Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333(21): 1374-9.
Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51(4): 1110-5.
Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 2000; 123 ( Pt 10): 2171-8.
Akyildiz B, Gümüs H, Kumandas S, et al. Guillain-Barré syndrome associated with Legionnella infection. J Trop Pediatr 2008; 54(4): 275-7.
Geurtsvankessel CH, Islam Z, Mohammad QD, Jacobs BC, Endtz HP, Osterhaus AD. Hepatitis E and Guillain-Barre syndrome. Clin Infect Dis 2013; 57(9): 1369-70.
van den Berg B, van der Eijk AA, Pas SD, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology 2014; 82(6): 491-7.
Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016; 387(10027): 1531-9.
Parra B, Lizarazo J, Jiménez-Arango JA, et al. Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. N Engl J Med 2016; 375(16): 1513-23.
Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry 2020.
Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 2014; 58(8): 1149-55.
Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010; 10(9): 643-51.
Salmon DA, Proschan M, Forshee R, et al. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013; 381(9876): 1461-8.
Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969; 48(3): 173-215.
Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39(5): 625-35.
Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30(2): 131-56.
Kokubun N, Shahrizaila N, Hirata K, Yuki N. Conduction block and axonal degeneration co-occurring in a patient with axonal Guillain-Barré syndrome. J Neurol Sci 2012; 319(1-2): 164-7.
Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM, Gershwin ME. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol 2016; 12(11): 1175-89.
Susuki K, Yuki N, Schafer DP, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 2012; 233(1): 534-42.
Willison HJ. The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy. J Peripher Nerv Syst 2012; 17 Suppl 3: 3-8.
Jacobs BC, Koga M, van Rijs W, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol 2008; 194(1-2): 181-90.
Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125(Pt 12): 2591-625.
Li S, Jin T, Zhang HL, et al. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments. Mediators Inflamm 2014; 2014: 740947.
van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7(10): 939-50.
Swaiman KF, Ashwal S, Ferriero DM, et al. Swaiman's Pediatric Neurology Principles and Practice- Inflammatory Neuropathies. 6 ed. China: Elsevier; 2017; 1086-92 p.
Lin JJ, Hsia SH, Wang HS, et al. Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol 2012; 47(2): 91-6.
Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol 2000; 15(3): 183-91.
Bordini BJ, Monrad P. Differentiating Familial Neuropathies from Guillain-Barré Syndrome. Pediatric Clinics of North America 2017; 64(1): 231-52.
Yıldırım Ç. Guillian Barre Sendromu ve Transvers Miyelit Olgularında Uzun Süre İzlem ve Tedavi Seçeneklerinin Etkiliğinin Karşılaştırılması, Tıpta Uzmanlık Tezi, Kayseri, 2021, pp. 1-32.
Korinthenberg R. Acute polyradiculoneuritis: Guillain-Barré syndrome. Handb Clin Neurol 2013; 112: 1157-62.
Ryan M, Kaplan SL, Shefner JM. Guillain-Barré syndrome in children: Epidemiology; clinical features, and diagnosis. UpToDate Waltham, Mass: UpToDate 2017; erişim tarihi: ekim 2021
Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109 ( Pt 6): 1115-26.
Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci 1993; 116(2): 185-92.
Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255(2): 57-65.
Bickerstaff ER. Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis. Br Med J 1957; 1(5032): 1384-7.
Bickerstaff ER, Cloake PCP. Mesencephalitis and Rhombencephalitis. British Medical Journal 1951; 2(4723): 77-81.
Michev A, Musso P, Foiadelli T, et al. Bickerstaff Brainstem Encephalitis and overlapping Guillain-Barré syndrome in children: Report of two cases and review of the literature. European Journal of Paediatric Neurology 2019; 23(1): 43-52.
Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70(1): 50-5.
Al-Din An, Anderson M, Bickerstaff Er, Harvey I. Brainstem Encephalitis And The Syndrome Of Miller Fisher A Clinical Study. Brain 1982; 105(3): 481-95.
Wakerley BR, Yuki N. Polyneuritis cranialis: oculopharyngeal subtype of Guillain-Barré syndrome. Journal of Neurology 2015; 262(9): 2001-12.
Polo A, Manganotti P, Zanette G, De Grandis D. Polyneuritis cranialis: clinical and electrophysiological findings. J Neurol Neurosurg Psychiatry 1992; 55(5): 398-400.
Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986; 43(11): 1150-2.
Mogale KD, Antony JH, Ryan MM. The pharyngeal-cervical-brachial form of Guillain-Barré syndrome in childhood. Pediatr Neurol 2005; 33(4): 285-8.
Yang J, Huan M, Jiang H, Song C, Zhong L, Liang Z. Pure sensory Guillain-Barré syndrome: A case report and review of the literature. Exp Ther Med 2014; 8(5): 1397-401.
Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997; 62(5): 529-31.
Nass R, Chutorian A. Dysaesthesias and dysautonomia: a self-limited syndrome of painful dysaesthesias and autonomic dysfunction in childhood. J Neurol Neurosurg Psychiatry 1982; 45(2): 162-5.
Yuki N, Odaka M, Hirata K. Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: clinical features. Ophthalmology 2001; 108(1): 196-200.
Kimachi T, Yuki N, Kokubun N, Yamaguchi S, Wakerley BR. Paraparetic Guillain-Barré syndrome: Nondemyelinating reversible conduction failure restricted to the lower limbs. Muscle Nerve 2017; 55(2): 281-5.
van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC. Paraparetic Guillain-Barré syndrome. Neurology 2014; 82(22): 1984-9.
Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43(10): 1911-7.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 Suppl: S21-4.
Vucic S, Cairns KD, Black KR, Chong PS, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 2004; 115(10): 2329-35.
Kokubun N, Shahrizaila N, Hirata K, Yuki N. Reversible conduction failure is distinct from neurophysiological patterns of recovery in mild demyelinating Guillain-Barré syndrome. J Neurol Sci 2013; 326(1-2): 111-4.
Coşkun A, Kumandaş S, Paç A, Karahan OI, Guleç M, Baykara M. Childhood Guillain-Barré syndrome. MR imaging in diagnosis and follow-up. Acta Radiol 2003; 44(2): 230-5.
Yikilmaz A, Doganay S, Gumus H, Per H, Kumandas S, Coskun A. Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst 2010; 26(8): 1103-8.
Mulkey SB, Glasier CM, El-Nabbout B, et al. Nerve root enhancement on spinal MRI in pediatric Guillain-Barré syndrome. Pediatr Neurol 2010; 43(4): 263-9.
Zuccoli G, Panigrahy A, Bailey A, Fitz C. Redefining the Guillain-Barré spectrum in children: neuroimaging findings of cranial nerve involvement. AJNR Am J Neuroradiol 2011; 32(4): 639-42.
Rajabally A. Yusuf et al Dysimmune Neuropathies -Guillain-Barré syndrome by Pieter A van Doorn ; Academic Press, Elsevier; 2020 page:5-31
Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nat Rev Dis Primers 2018; 4(1): 31.
Sheikh KA. Guillain-Barré Syndrome. Continuum (Minneap Minn) 2020; 26(5): 1184-204.
Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978; 2(8093): 750-3.
van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007; 6(7): 589-94.
Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991; 14(11): 1103-9.
Ryan M, Randolph AG, Shefner JM. Guillain-Barré syndrome in children: Treatment and prognosis. UpToDate; 2017; erişim tarihi: ekim 2021
Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005; 116(1): 8-14.
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997; 349(9047): 225-30.
Saritas Nakip O, Kesici S, Bayrakci B. Zipper method is the emerging treatment option for severe Guillain-Barre syndrome related COVID-19. Autoimmun Rev 2021; 20(7): 102841.
Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021; 20(4): 275-83.
Osman C, Jennings R, El-Ghariani K, Pinto A. Plasma exchange in neurological disease. Pract Neurol 2020; 20(2): 92-9.
Hughes RA, van Der Meché FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev 2000; (3): Cd001446.
Ryan MM. Pediatric Guillain-Barré syndrome. Current Opinion in Pediatrics 2013; 25(6): 689-93.
